HOXD9 promotes the growth, invasion and metastasis of gastric cancer cells by transcriptional activation of RUFY3

Huiqiong Zhu, Weiyu Dai, Jiaying Li, Li Xiang, Xiaosheng Wu, Weimei Tang, Yaying Chen, Qiong Yang, Mengwei Liu, Yizhi Xiao, Wenjing Zhang, Jianjiao Lin, Jing Wang, Guangnan Liu, Yong Sun, Ping Jiang, Guoxin Li, Aimin Li, Side Liu, Ye Chen, and Jide Wang

Abstract

Background: The transcription factor HOXD9 is one of the members of the HOX family, which plays an important role in neoplastic processes. However, the role of HOXD9 in the growth and metastasis of gastric cancer (GC) remains to be elucidated.

Methods: In vitro functional role of HOXD9 and RUFY3 in GC cells was determined using the TMA-based immunohistochemistry, western blot, EdU incorporation, gelatin zymography, luciferase, chromatin Immunoprecipitation (ChIP) and cell invasion assays. In vivo tumor growth and metastasis were conducted in nude mice.

Results: HOXD9 is overexpressed in GC cells and tissues. The high expression of HOXD9 was correlated with poor survival in GC patients. Functionally, HOXD9 expression significantly promoted the proliferation, invasion and migration of GC cells. Mechanically, HOXD9 directly associated with the RUFY3 promoter to increase the transcriptional activity of RUFY3. Inhibition of RUFY3 attenuated the proliferation, migration and invasiveness of HOXD9-overexpressing GC cells in vitro and in vivo. Moreover, both HOXD9 and RUFY3 were highly expressed in cancer cells but not in normal gastric tissues, with their expressions being positively correlated.

Conclusions: The evidence presented here suggests that the HOXD9-RUFY3 axis promotes the development and progression of human GC.

Keywords: HOXD9, RUFY3, Gastric cancer, Proliferation, Metastasis

Introduction

Homeobox (HOX) genes encode a highly conserved family of transcription factors that significantly influence many cellular processes, including proliferation [1], apoptosis [2], cell shape [3], and cell migration [4]. HOX genes contain a conserved 183 bp sequence and encode nuclear proteins called homeoproteins [5, 6]. HOX proteins regulate the expression of many downstream target genes. Novel evidence has confirmed the involvement of the dysregulated expression of HOX genes in cancer [4–6]. HOX genes are a family of 39 transcription factors that are divided into four clusters (HOXA to HOXD); during normal development, these genes regulate cell proliferation and specific cell fates [7].

The transcription factor HOXD9 is one of the members of the HOX family, which has emerged as a family of important transcriptional regulators [8–10]. HOXD9 participates in the development and progression of some cancers. Studies have demonstrated that HOXD9 contributes to both cell proliferation and/or cell survival in gliomas [8]. Moreover, the HOXD9 expression level was higher in esophageal cancer tissues than that in normal tissues [9]. Furthermore, HOXD9 exhibited high expression in invasive HCC cells, and HOXD9 overexpression can significantly enhance HCC cell migration, invasion, and metastasis [10]. The transcription factor HOXD9 binds to a DNA consensus sequence (5′- AATAAAAATA - 3′) (http://alggen.lsi.upc.es/cgi-bin/
were maintained at 37 °C in a 5% CO₂ atmosphere in sources Cell Bank, Osaka, Japan) were obtained. Cell lines 45 and MKN-28 (Japanese Collection of Research Biore- China), Rabbit anti-RUFY3 (H-140) and horseradish peroxidase-conjugated anti-rabbit, mouse anti-Cyr61 (H-78), anti-FOXK1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-β-Tubulin (RM2003) was purchased from Ray antibody Biotech. The specific phospho-ERK inhibitor PD98059, phospho-JNK specific inhibitor SP600125 and phospho-p38 specific inhibitor SB203580 were purchased from Calbiochem (Merck KGaA, Darmstadt, Germany).

Tissue multi-array (TMA) and immunohistochemical analysis
Immunohistochemical staining on tissue microarray of GC was carried out as described previously [17]. See Additional file 1: Supplementary Materials and Methods.

Plasmids construction
Normal human complementary DNA (cDNA) corresponding to the full-length HOXD9 was obtained by RT-PCR amplification. The PCR products were sub-cloned into mammalian expression vector pENTER-FLAG (ViGene Biosciences, Rockville, MD, USA). Populations of pENTER vector and pENTER HOXD9 stable transfecants were obtained using the same plasmid and selection process. Cell transfection was performed with Lipofectamine TM 2000 (Invitrogen) as described in the manufacturer’s protocol.

RNA isolation, RT-PCR, and real time PCR
Using motorized homogenizer, the snap frozen tissue (~100 mg) was ground and total RNA was isolated using Tri-reagent (Sigma Aldrich, St Louis, MO, USA) according to manufacturer’s protocol. cDNA was synthesized from 1 μg of total RNA using GeneAmp RNA PCR cDNA synthesis kit (Applied Biosystems, Carlsbad, CA, USA). Each cDNA sample was processed in duplicate for each q-RT-PCR assay, and the average relative fold mRNA expression levels were determined using the 2-ΔΔCₚ method, with GAPDH as the internal control. The primers used are listed in Additional file 1: Table S1.

Western blot analysis
Cell lysates were prepared using lysis buffer with 1%NP40 detergent, 0.5% sodium deoxycholate, 0.1% SDS,50 mM sodium fluoride, 1 mM sodium orthovanadate,10 mM sodium pyrophosphate (Sigma Aldrich) and protease inhibitors (Roche). Protein was quantified with Bradford reagent and equal amount of protein was resolved by SDS-PAGE using Bio-Rad apparatus, transferred to PVDF membrane (Millipore, Billerica, MA, USA) and probed with appropriate antibodies. HRP coupled secondary antibodies were obtained, and proteins were visualized using the enhanced chemiluminescence detection system.
Gene silencing using siRNA

HOXD9 siRNA and Scrambled control siRNA were purchased from Genepharma Company (Suzhou, China). The sequences of the siRNA were as follows (sense strand): HOXD9-specific siRNA (875- CACCAAAUAC CAGACGGCUU -894); RUFY3 siRNA 1: 1295-GACTAA TCAGATGCTGCTACCA-1318; RUFY3 siRNA 2:194-GGCTAATGAACGGCATGAAC-213 and src siRNA, 5’-TTCCTCGAAGCGTGTACGT-3’. The siRNA was transfected into the cells with lipofectamine, following the protocols provided by the manufacturer.

Cell proliferation assay and colony forming assay
See Additional file 1: Supplementary Materials and Methods.

EdU incorporation assay
See Additional file 1: Supplementary Materials and Methods.

Invasion and cell migration assays

Invasion and cell migration assays were performed as described [4, 18]. The cells were plated in serum-free medium on Transwell inserts (Corning, NY) coated with 25 μg of Matrigel (BD Biosciences) for invasion assays. After incubation for 48 h at 37 °C/5% CO2, the inserts were fixed with 3% paraformaldehyde/PBS and stained with 2% crystal violet. The number of cells that had invaded was counted in five representative (×200) fields per insert (invasion index, %). Cell migration assays were performed. Briefly, the cells plated in six well plates with 100% confluence were wounded with a pipette tip at time 0. The media were changed to remove cell debris, and the cells were cultured in the presence of 10 μg/ml mitomycin C to inhibit cell proliferation. Photographs were taken 72 h later.

Gelatin zymography assay

The production of MMPs (MMP2 and MMP9) in GC cells was analyzed by gelatin zymography. GC cells were grown to 70% confluence, washed twice with 1 × PBS, and incubated in serum-free medium. After 24 h, the conditioned medium was collected and concentrated with a centrifugal filter (Millipore, MA, USA) under 6000 g for 15 min. Gelatin zymography assays were performed using commercial kits (Novex 10% Gelatin Gel, Invitrogen). The gel was stained with Coomassie blue. Densitometry was used to quantify the MMP bands.

Luciferase assay

First, 104-bp (RUFY3p1) and 345-bp (RUFY3p2) fragments of the RUFY1 promoter upstream of the transcription start site were cloned into the pGL3basic vector. For the luciferase assay, the cells were transiently transfected with the various pLuc constructs with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Luciferase activity was measured sequentially from a single sample using the Dual-Glo™ Luciferase Assay System (Promega) as described previously [19]. The firefly luciferase activity was normalized against Renilla activity, and the relative amount of luciferase activity in the untreated cells was designated as 1. The luminescence was measured with a dual luminometer (TD-20/20, EG&G, Berthold, Australia).

The mutant RUFY3 promoter reporter construct was generated from the RUFY3p1 and RUFY3p2 constructs by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). All mutations were verified by sequencing. The primer sequences are listed in the Additional file 1: Table S1.

ChIP assay
See Additional file 1: Supplementary Materials and Methods. The primers and antibodies used in the ChIP assays are listed in the Additional file 1: Table S1.

Lentivirus preparation

Lentivirus expressing EGFP/HOXD9 (LV-HOXD9) was constructed by Genechem (Shanghai, China) using Ubi-MCS-3FLAG-CBh-gcGFP-RES-puromycin vector. Ubi-MCS-3FLAG-CBh-gcGFP-RES-puromycin empty vectors were used as controls (Shanghai Genechem Co. Ltd., China). Double-stranded oligonucleotides encoding human RUFY3-shRNA (NM_001037442: CCGGGACTAATCAGATGGCTGCTACCATCAAGAGTGGTAGCAGCCATCTGATTA GTCTTTTG) were annealed and inserted into the short hairpin RNA (shRNA) expression vector U6-MCS-Ubiquitin-Cherry-RES-puromycin. Selected pools of overexpressing and knockdown cells were used for subsequent experiments.

In vivo tumorigenesis in nude mice

A total of 1 × 107 logarithmically growing AGS cells transfected with LV-EGFP/HOXD9 + src-shRNA, LV-EGFP/HOXD9 + RUFY3-shRNA and the control LV-EGFP/vector (N = 3) in 0.1 ml RPMI 1640 medium were subcutaneously injected into the left-right symmetric flank of 4–6-week-old male BALB/c nu/nu mice. The animals were fed with an autoclaved laboratory rodent diet. Tumors were measured with calipers every 3–5 days after injection, and the tumor volumes were calculated according to the following formula: 0.5 × length × width². All animal studies were conducted in accordance with the principles and procedures outlined in the Southern Medical University of China Guide for the Care and Use of Animals. After 25 days, the mice were sacrificed. Tumor tissues were excised and weighted.

In vivo metastasis assay

To investigate the role of RUFY3 in HOXD9-mediated metastasis in vivo, we have established both tail-vein model and orthotopic implantation model which resulted in lung or liver metastasis by human GC cells. To assess
the effect on lung metastasis, we divided in 3 experimental groups (EGFP/vector, EGFP/hoXd9 + src-shRNA and EGFP/hoXd9 + RUFY3-shRNA in 5 × 10⁶/ml cells) with 3 animals each group and injected via the tail vein. The progression of cancer cell growth was monitored after 42 days by bioluminescent imaging using the IVIS100 Imaging System (Kodak, Rochester, NY, USA).

To evaluate the effect on liver metastasis, we injected subcutaneously into the right flank of nude mice (N = 6 per group). Six-eight weeks later, when the size of tumor was around 1 cm³, tumor mass from each group was taken out and minced into pieces of approximately 1 mm³ for use in transplantation. Then, the stomach was exteriorised through a small midline laparotomy and a piece of tumor tissue sutured to the greater curvature side of the gastric antrum surface with a single Maxon 7/0 suture. After implantation, the abdominal wall was closed in two layers with Dexon 5/0. Mice were sacrificed at 6th post-operative week. Four mm paraffin-embedded sections of lung and liver tissues were prepared. The sections were stained with HE and IHC and examined for the presence of metastatic tumor foci under microscopy.

Statistical analysis
Statistical analyses were performed using the SPSS statistical software package (standard version 20.0 PSS, Chicago, IL). Quantitative data obtained from experiments with biological replicates are shown as the mean ± standard deviation. The survival rates were calculated by Kaplan-Meier curves, and log-rank tests were used to examine the differences in survival rates between the two groups. Two-tailed Student's t-test was used to analyze the quantitative data, with significant differences being considered if P values were < 0.05.

Results
HOXD9 is overexpressed in gastric cancer tissues and GC cell lines
In the firebrowse database (http://firebrowse.org/), HOXD9 is upregulated in gastric (STAD), stomach and esophageal (STES), thyroid (THCA), bladder urothelial (BLCA), bile duct (CHOL), esophageal (ESCA), head and neck (HNSC), hepatocellular (LIHC), lung adenocarcinoma (LUAD) and lung squamous (LUSC) cancer tissues compared with that in corresponding normal tissues (Fig. 1d). We confirmed the induced expression of eight transcription factor oncogenes after ectopic HOXD9 expression in GC cells. The mRNA expression of the endogenous FOXK1, KLF8, Snail, Slug, Sp1, Sp3, YY1 and HMGA1 genes were upregulated in stable HOXD9 transfectants of GC cells (Fig. 1f).

We then measured HOXD9 expression in matched gastric normal (N) and cancerous (T) tissues by Western blot. We proved that eight of ten samples of GC specimens showed higher expression of HOXD9 protein than adjacent normal tissues (Fig. 1b).

To further evaluate the effect of HOXD9 expression on GC progression and metastasis, we investigated the expression of HOXD9 protein with a 90-primary GC tissue microarray (TMA). We observed HOXD9-positive staining in tumor cells and tumor-associated stroma cells (TAS; arrow) and HOXD9-negative or weak HOXD9-positive staining in adjacent normal gastric cells as exemplified in Fig. 1c. Semiquantitative scoring showed that HOXD9 protein was expressed at significantly higher levels in cancer tissues than that in adjacent normal gastric mucosa tissues by TMA assay (Fig. 1d).

To validate our findings in vivo, we examined HOXD9 expression in regional lymph nodes and metastatic cancer tissues from two patients (Fig. 1e). HOXD9 was expressed at high or intermediate levels in cancer cells. These results suggest that HOXD9 is upregulated in human GC.

Finally, we transfected the GC cells with empty (vector) plasmid and plasmids encoding HOXD9 protein into GC cells. After selection with antibiotics, we obtained a pooled cloned cell line that stably expressed HOXD9. We confirmed the induced expression of eight transcription factor oncogenes after ectopic HOXD9 expression in GC cells. The mRNA expression of the endogenous FOXK1, KLF8, Snail, Slug, Sp1, Sp3, YY1 and HMGA1 genes were upregulated in stable HOXD9 transfectants of GC cells (Fig. 1f).

These results support the hypothesis that HOXD9 might play a role in the tumorigenesis of gastric cancer.
80-month survival rate than those with low HOXD9 expression (Fig. 2b). Such a relationship was observed in patients with late-stage GC (AJCC stage III and IV)\((P = 0.0175, \text{Fig. 2d})\), but it was less obvious in those with early-stage GC (AJCC stage I and II)\((P = 0.0052)\) (Fig. 2c). Similar to the results from the KM-Plotter database (http://kmplot.com/analysis/index.php?p=service&start=1) (Additional file 3: Figure S2A) and TCGA dataset (http://xena.ucsc.edu/public, Additional file 3: Figure S2B), there was a significant difference between the HOXD9 high-expression group and the HOXD9 low-expression group. High-expression of HOXD9 gene in overall survival (OS) of GC patients predicts poor prognosis than low-expression HOXD gene at mRNA level (Additional file 3: Figure S2A & B).

These findings indicate that HOXD9 expression plays a critical role in GC development and progression and is a valuable prognostic biomarker for this disease.

**The expression of HOXD9 is correlated with the malignant biological behavior in GC**

Given the increased expression of HOXD9 in the GC tissues, we evaluated the functional effect of HOXD9 overexpression on cell behaviors in vitro. We first established pooled- stable transfectants with HOXD9-sense and vector plasmids to verify the protein expression levels. The results indicated that overexpression of exogenous HOXD9 were confirmed by western blot analysis the GC cell lines (Fig. 3a). Subsequently, GC cells proliferation were evaluated. As illustrated in Fig. 3b and Additional file 4: Figure S3A, HOXD9 overexpression resulted in an increased number of colonies compared with cells transfected with empty vector in a colony forming assay. The forced expression of HOXD9 significantly enhanced GC cellular growth rates, with the highest increased peak at 72 h at the determined time periods in this study compared to those of empty vectors using the CCK-8 assay (Fig. 3c). Similarly, the proliferation rate of GC cells transfected with HOXD9 was significantly increased.
compared to that of the empty vector by using an EdU assay (Fig. 3d and Additional file 4: Figure S3B). The result indicates that HOXD9 overexpression can lead to increased GC cell growth.

Lv X et al. have demonstrated that HOXD9 promotes the migration and invasion of liver cancer cells [10]. Motivated by this previous study, we studied the effect of HOXD9 on the migration and invasion of GC cells. As shown in Fig. 3e, the forced expression of HOXD9 significantly enhanced the migratory capacity of GC cells (Fig. 3e and Additional file 4: Figure S3C). Moreover, we examined its cell invasion activity in vitro. After ectopic expression of HOXD9, the invasiveness of GC cells was increased compared with that of control cells (Fig. 3f and Additional file 4: Figure S3D).

A previous report showed that most cancers are associated with deregulation of the MAPK/ERK (ERK, JNK, and p38) signaling pathways [20]; thus, we explored the mechanism of HOXD9’s effect on proliferation and migration in GC cells. The ectopic expression of HOXD9 enhanced the phosphorylation levels of extracellular signal-regulated protein kinase (ERK1/2) and c-Jun N-terminal kinase (JNK). However, the overexpression of HOXD9 was associated with unchanged phosphorylation levels of p38 mitogen-activated protein kinases (p38) by Western blot (Fig. 3g). Then, we treated the cells with the ERK1/2 inhibitor U0126, the JNK inhibitor SP600125 or the p38 inhibitor SB203580 for 2 days. Inhibitor U0126, SP600125 or SB203580 treatment inhibited the activation of p-ERK, p-JNK and p-p38, but ERK, JNK and p38 levels remained unchanged.

These studies suggest that HOXD9 promotes the proliferation and invasive capacity of GC cells.

RUFY3 is a direct target of transcriptional activation by HOXD9

We previously reported that genes such as Cyr61, FHL2, Vimentin, FOXK1 and RUFY3 are implicated in the pathogenesis of gastrointestinal cancers [14, 17, 18, 21, 22]. As a transcription factor, HOXD9 may regulate downstream genes; thus, we further assessed whether the overexpression or knockdown of HOXD9 modulated the expression of a panel of genes (Cyr61, FHL2, Vimentin, FOXK1 and RUFY3) in GC cells. We showed that the up-regulation of HOXD9 significantly increased the expression of FOXK1, Vimentin and RUFY3, whereas the downregulation of HOXD9 decreased FOXK1, Vimentin and RUFY3 expression. In contrast, the protein expression level of FHL2 and Cyr61 remained unchanged upon HOXD9 overexpression or knockdown (Fig. 4a). Therefore, we wondered whether the transcription factor HOXD9 could directly regulate RUFY3 in GC cells.

We studied the interaction between RUFY3 and HOXD9 proteins, and there was no association using the STRING database (https://string-db.org/cgi/input.pl). We next assessed whether HOXD9 proteins could directly bind to the RUFY3 promoter.

We scanned the proximal 1250 bp of the promoter region of RUFY3 using Promo software (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/ promoinit.cgi?dirDB = TF_8.3) and identified the following three potential HOXD9 binding sites: site 1 (RUFY3p1), +294 ~ +303; and site 2 (RUFY3p2), −104 to −95; and site 3 (RUFY3p3), −345 to −336 (numbering is from the transcription start site; Fig. 4b). The luciferase reporter assay showed that the activity of RUFY3p1 and RUFY3p2 in HOXD9 cells increased approximately 5 ~ 14-fold in AGS and 6 ~ 15 fold in BGC-823 cells compared with that in vector control cells, whereas the magnification exhibited a slight decrease with RUFY3p3. Site-directed mutagenesis showed that the first and second HOXD9-binding site were critical for HOXD9-induced RUFY3 transactivation (Fig. 4b).

Next to investigate whether HOXD9 could physically bind to the RUFY3 promoter in vivo, we performed chromatin immunoprecipitation (ChIP) -qPCR assays in

| Table 1 Correlation between HOXD9 protein expression and the clinicopathological parameters of gastric carcinoma |
|---------------------------------|-----------------|-----------------|-----|
| Features                                      | Total number (n = 90) | HOXD9 Expression | P  |
|                                              |                  | Low  | High |     |
| Age (years)                                   |                  |      |      |     |
| <60                                           | 35               | 12 (34.3%) | 23 (65.7%) | 0.475 |
| ≥60                                           | 55               | 23 (41.8%) | 32 (58.2%) |     |
| Gender                                        |                  |      |      |     |
| Male                                          | 53               | 23 (43.3%) | 30 (56.6%) | 0.294 |
| Female                                        | 37               | 12 (32.4%) | 25 (67.6%) |     |
| Differentiation                               |                  |      |      |     |
| Well                                          | 29               | 22 (75.9%) | 7 (24.1%)  | <0.001 |
| Moderate                                      | 17               | 8 (47.1%)  | 9 (52.9%)  |     |
| Poor                                          | 44               | 5 (5.6%)  | 39 (88.6%) |     |
| Lymph node metastasis                        |                  |      |      |     |
| Yes                                           | 67               | 15 (22.4%) | 52 (77.6%) | <0.001 |
| No                                            | 23               | 20 (87.0%) | 3 (13.0%)  |     |
| Tumor size (cm³)                              |                  |      |      |     |
| <10                                           | 24               | 16 (66.7%) | 8 (33.3%)  | 0.001 |
| ≥10                                           | 66               | 19 (28.8%) | 47 (52.2%) |     |
| AJCC stage                                    |                  |      |      |     |
| T1, T2                                        | 14               | 11 (78.6%) | 3 (21.4%)  | 0.001 |
| T3, T4                                        | 76               | 24 (31.6%) | 52 (68.4%) |     |
| AJCC TNM stage                                |                  |      |      |     |
| I, II                                         | 36               | 27 (75.0%) | 9 (25.0%)  | <0.001 |
| III, IV                                       | 54               | 8 (14.8%)  | 46 (85.2%) |     |
human tumor cell lines expressing endogenous HOXD9. PCR primers located in exon 3 of RPL30 and anti-Histone H3 antibody served as the positive control. The primers were used to amplify the sequence containing the distant upstream of RUFY3 promoter served as the negative control. qPCR amplification showed that the first (+294 to +303) and the second (−104 to −95) possible binding sites were immunoprecipitated. Normal rabbit IgG was used as the negative control. No bands were evident in the immunoprecipitates for the third (−345 ~ −336) possible binding site for the control IgG (Fig. 4c). These studies suggest that HOXD9 transactivates RUFY3 expression.

RUFY3 promotes GC development and progression by regulating HOXD9
To demonstrate whether RUFY3 is required for HOXD9's effect on the development and progression of GC, we designed two siRNAs (RUFY3 siRNA1 and RUFY3 siRNA2) with different sequences for the RUFY3 RNAi experiments, and both of these successfully suppressed the expression of RUFY3 (Fig. 5a). Then, we revealed that the the downregulation of RUFY3 in HOXD9-overexpressing cells (HOXD9-RUFY3-siRNA1 and HOXD9-RUFY3-siRNA2) caused a decrease in the proliferation of GC cells (Fig. 5b, c and Additional file 5: Figure S4A & B).

Similar results were observed, where the induction of metastatic phenotypes caused by the overexpression of HOXD9 was abolished by the repression of RUFY3, as shown by migration and invasion assays (Fig. 5d and Additional file 5: Figure S4C, Fig. 5e and Additional file 5: Figure S4D).

We also tested the activities of MMP2 and MMP9 in the vector cells as well as the overexpression of HOXD9 and the knockdown of RUFY3 in HOXD9-overexpressing GC cells. We found that HOXD9 overexpression in GC cells significantly elevated the activities of MMP2 and MMP9, as indicated via gelatinolytic assays, compared with that in empty-vector-expressing cells, whereas RUFY3 knockdown in HOXD9-overexpressing cells led to a loss of the enzymatic activities of MMP2 and MMP9 (Fig. 5f & g). Taken together, these results demonstrate that the effect of RUFY3 on the cell proliferation, migration and invasion of GC cells is caused by the expression of HOXD9.

Fig. 2 HOXD9 is upregulated in gastric cancer tissues and associated with poor prognosis. a TMA representative images of IHC staining of HOXD9 in GC tissue. a Negative HOXD9 expression; (b) weak HOXD9 expression; (c) moderate HOXD9 expression; (d) strong HOXD9 expression in GC. Scale bars, 50 mm in A. Kaplan–Meier survival analysis of overall survival in all patients (b), the patients at the early stage of GC (c) and the patients at the late stage of GC (d) according to HOXD9 expression. The log-rank test was used to calculate P-values.
RUFY3 is essential for the induction of tumorigenesis and metastasis by HOXD9 in vivo

To verify whether RUFY3 is required for HOXD9 in the growth and metastasis of GC cells, we deployed a RUFY3 loss-of-function strategy in HOXD9-expressing AGS cells in vivo. The cells stably expressing LV-vector, LV-HOXD9 src-shRNA or LV-HOXD9-RUFY3-shRNA in three groups were injected subcutaneously into the right flank of each nude mouse, as shown in Fig. 6a and Additional file 6: Figure S5A & B. The tumor volumes of the HOXD9-overexpressing cells were markedly greater than those of the vector-expressing cells. In contrast, tumors derived from RUFY3 downregulation in HOXD9-overexpressing cells were markedly smaller than those of the vector-treated mice at 20 to 25 days (Additional file 6: Figure S5C & D).

Next, we examined the protein expression of cell proliferation (Ki-67) and angiogenesis (CD105) markers in the xenograft tumor. LV-HOXD9 cell groups was increased compared to that in LV-vector cells, whereas RUFY3 knockdown decreased the proliferation rate and tumor vessel density in the HOXD9-overexpressing group (Fig. 6b & c).

To test the role of RUFY3 in HOXD9-mediated tumor progression, we have established tail-vein metastasis model and orthotropic implantation model using human gastric cancer AGS cells in nude mice, which resulted in lung and liver metastases (Fig. 6d and Additional file 6:...
Figure S5E & F). The number of lung or hepatic metastatic lesions in mice injected with LV-HOXD9 cells was increased compared to LV-vector cells, whereas knockdown of RUFY3 in HOXD9-overexpressing cells decreased the number of metastatic loci in HOXD9-overexpressing cells (Fig. 6e and Additional file 6: Figure S5G). The presence of metastasis from GC to the lung and liver was confirmed by histological analysis (Fig. 6f and Additional file 6: Figure S5H). We next examined the expression of cell metastasis markers (MMP-2 and MMP-9) by qPCR and IHC. HOXD9-overexpressing group resulted in a significant increase in MMP2 and MMP9 levels, whereas downregulation of RUFY3 in HOXD9-overexpressing group caused a decrease in MMP2 and MMP9 levels in GC tissues in xenograft tumors. (Fig. 6g and Additional file 6: Figure S5I, J & K). MMP2 and MMP9 were expressed at high levels in GC tissues than normal tissues in nude mice (Fig. 6h and Additional file 6: Figure S5L, M & N).

Taken together, these results indicate that the HOXD9-RUFY3 axis contributes to progression and metastasis in vivo.

**HOXD9 expression positively correlates with RUFY3 expression in GC tissue**

We analyzed both HOXD9 and RUFY3 expression in 11 samples of GC tissues. By analyzing consecutive primary GC sections, we observed that HOXD9 expression was significantly positively correlated with RUFY3 expression. GC but not adjacent tissues expressed both HOXD9 and RUFY3. (Fig. S5J & K).
RUFY3, as exemplified in Fig. 7a. Semiquantitatively scoring the two proteins showed that the expression levels of both proteins in cancerous tissues were significantly higher than those of adjacent normal gastric tissues (Fig. 7b), while Spearman correlation analysis showed a positive correlation between HOXD9 and RUFY3 expression (correlation coefficient $r = 0.886$, Fig. 7c).

Furthermore, we examined the expression of HOXD9 and RUFY3 in serial sections of lymph node metastatic cancer tissues from two patients. The results showed that a high level of HOXD9 expression positively correlates with RUFY3 expression in lymph node metastases (Fig. 7d).

We had previously shown that activation of the MAPK/ERK pathway is involved in the regulation of cell proliferation, invasion and metastasis in GC (Fig. 3f). We next wondered whether HOXD9 and RUFY3 participated in the MAPK/ERK pathway. The results of Western blots showed that the ectopic expression of HOXD9 led to high phosphorylation levels of p-JNK and p-ERK1/2 compared with that observed in vector cells. However, the p-JNK and p-ERK1/2 phosphorylation levels were downregulated after RUFY3 knockdown in HOXD9-overexpressing cells compared with those in HOXD9-overexpressing cells, and the phosphorylation levels of p-p38 and the total protein levels of JNK, ERK1/2, p38 were unaltered (Fig. 7f).

Together, the data suggest that the expression of HOXD9 is correlated with the expression of RUFY3; thus, the HOXD9–RUFY3 axis has an important role in development and metastasis during GC.
Fig. 6 (See legend on next page.)
Discussion

HOX genes, a highly conserved subgroup of the homeobox superfamily, play crucial roles in embryogenesis and tumorigenesis, which share the same requirements such as growth and differentiation. HOX genes that are critical for embryonic development are expressed aberrantly in abnormal development and malignancy, indicating that the altered expression of HOX genes is important for oncogenesis. Numerous examples of aberrant HOX gene expression have been found in various types of cancer, including lung [4], colorectal [23], liver [24] and breast cancers [25]. In the present study, we demonstrated that HOXD9 was upregulated in GC, and patients with a high level of expression of HOXD9 had a poorer prognosis than those with a low level of expression. Furthermore, ectopic expression of HOXD9 in GC cells promoted the proliferation and migration. Moreover, our data showed that HOXD9 transactivated RUFY3 expression. Therefore,
HOXD9 may play a critical role in RUFY3-mediated tumor growth and metastasis in vitro and in vivo. 

As a member of the HOX family, HOXD9 has been found to be deregulated in several cancers including cervical [26], glioma [9] ovarian [27] and liver cancers [10]. However, the role of HOXD9 in GC is still not well characterized. In this study, we found that HOXD9 was overexpressed in both GC cell lines and tissues.

Kaplan-Meier analysis of the survival curves showed a significantly worse overall survival for patients whose tumors had high HOXD9 levels, indicating that a high HOXD9 tumor protein level is a marker of poor prognosis for patients with GC. Tabuse M et al. showed that HOXD9 promotes glioma cell proliferation, and the knockdown of HOXD9 in glioma cells using HOXD9-specific siRNA resulted in decreased cell proliferation, cell cycle arrest, and the induction of apoptosis [9]. Consistent with this, we showed that HOXD9 promotes GC cell proliferation and that tumors with upregulated HOXD9 tended to display more aggressive behavior. The effect on cell growth, invasion, and metastasis also indicates that HOXD9 functions as an oncogene in cancer cells. All these data suggest that HOXD9 expression is elevated in GC and plays an important role in GC development and progression. 

MAPKs are serine/threonine protein kinases, and they can be activated by many stimuli including cytokines [28], growth factors [29], neurotransmitters [30], hormones [31], stress [32], and adhesion [33]. Therefore, MAPKs can be involved in the process of cell division. The MAPK family is divided into three subfamilies: ERK1/2, JNK and p38 [20]; they are involved in many reactions affecting cell proliferation [34], differentiation [35], and apoptosis [36] in mammals. Many studies have confirmed that the MAPK signaling pathway is activated in GC [37], lung cancer [38], ovarian cancer [39], and liver cancer [40]. Therefore, we speculated that HOXD9 might be a downstream factor of MAPK pathways. In this study, we examined the phosphorylation of multiple MAPKs, including ERK1/2, JNK and p38 in GC cell lines. Our results identified important roles for the ERK and JNK signaling pathways in the HOXD9-mediated aggressive behavior of GC cells since there was a dramatic increase in the phosphorylation of ERK and JNK in GC HOXD9-transfected cells compared to that in control vector cells. However, p38 phosphorylation was not changed, suggesting that it is not involved in HOXD9-mediated GC cell metastasis and proliferation. In addition, pretreatment of cells with SP600125 and U0126 resulted in blockade of the increase in HOXD9 expression. Our findings imply that HOXD9 is a positive regulator of the ERK and JNK signaling pathways in vitro. 

RUFY is a member of the RUN domain-containing protein family and has been implicated in various biological processes, including embryonic development, cell differentiation, proliferation and apoptosis. It also plays an important role in neoplastic processes such as cell growth, migration and invasion [5, 41, 42]. For example, Zhi Q et al. showed that podocalyxin-like protein promotes gastric cancer progression through interacting with RUFY1 [41]. Wang G et al. also revealed that RUFY3 overexpression promotes gastric cancer cell migration and invasion [5]. However, the roles of HOXD9-RUFY3 axis in GC are still not well characterized. Here, we demonstrated that the forced expression of HOXD9 could also increase the activity of RUFY3 promoter in GC cells, which is in agreement with recent studies, showing that HOXD9 translationally regulates ZEB1 in HCC [10]. Moreover, mutations in the site significantly attenuated the HOXD9-mediated transactivation of the human RUFY3 promoter, and ChIP assays confirmed the recruitment of HOXD9 to the binding site in the human RUFY3 promoter. These studies suggested that RUFY3 was a direct transcriptional target of HOXD9. In addition, abnormal expression of RUFY3 dramatically regulated HOXD9-mediated on the malignant biological behavior of GC in vitro and in vivo. Besides, HOXD9 expression was positively correlated with RUFY3 expression in GC tissue. These results implicated that HOXD9 promotes GC tumorigenesis and metastasis by transactivating RUFY3.

Conclusions

In summary, we present a novel molecular basis for the role of HOXD9 in GC carcinogenesis, invasion and metastasis. The HOXD9 protein may enhance the malignant properties of tumor cells via its transactivation of the RUFY3 proto-oncogene. Knowledge of the interrelationship between HOXD9 and RUFY3 should greatly advance our understanding of the cellular and molecular mechanisms underlying the biological functions of HOXD9 in GC cells.

Additional files

Additional file 1: Supplementary Materials and Methods. Table S1. Primary Primers Used in This Study. (DOX 23 kb)

Additional file 2: Figure S1. HOXD9 is overexpressed in tumor tissues. The expression pattern of HOXD9 mRNA in normal and tumor tissues. HOXD9 mRNA expression in various types of cancer was searched in the firebrowse database (http://firebrowse.org/). (TIF 3019 kb)

Additional file 3: Figure S2. Kaplan-Meier curves for overall survival (OS) from the KM-Plotter database (http://kmplot.com/analysis/index.php?p=service&start=1) (Fig. 2a) and TCGA dataset (http://xena.ucsc.edu/public, Fig. 2b). (TIF 448 kb)

Additional file 4: Figure S3. Functional analysis of HOXD9 in vitro. (A) The GC cells (5 x 10^5) were plated in a tissue culture dish with complete culture medium for 14 days. Cell colonies were visualized after staining with 0.005% crystal violet. *** P<0.001. (B) DNA synthesis in GC cells was measured by Edu incorporation assay at 48 h after the indicated transfection. **** P<0.001, HOXD9 vs Vector. (C) Overexpression of HOXD9 led to a significantly quicker migration at 36 and 72 after transfection. *** P<0.01 and **** P<0.001. (D) Ectopic expression of HOXD9 led to an increased invasive ability of GC cells. Data are represented as normalized invasion (invasion index) relative to the control cells. **** P<0.001. The experiments were repeated at least three times. (TIF 470 kb)
Additional file 5: Figure S4. HOXD9-RUFY3 axis promotes the growth and invasion of GC cells. (A) Soft agar colony formation assays using the indicated cell clones. Quantification of colony numbers is presented. The data are presented as the means ± SD, ****, P < 0.001. (B) DNA synthesis in GC cells was measured by EdU incorporation assay. ****, P < 0.001. (C) The stable HOXD9 transfectants with RUFY3 siRNA1 and siRNA2 led to a significantly slower migration compared with HOXD9-overexpressing cells. ***, P < 0.001 and ***, P < 0.001. (D) The stable HOXD9 transfectants with RUFY3 siRNA1 and siRNA2 led to a reduced invasive ability compared with HOXD9-overexpressing cells. ***, P < 0.001. (TIF 623 kb)

Additional file 6: Figure S5. RUFY3 facilitates HOXD9-mediated cell proliferation and metastasis in GC in vivo. (A) & (B) The AGS cells (5 × 10^4) were injected subcutaneously in the right flanks of nude mice. Images shown were captured on day 25 after injection. (C) & (D) Tumor size was measured 5 days after tumor cell inoculation in each group. ***, P < 0.001, vector vs. HOXD9 and HOXD9 src-shRNA vs. HOXD9-RUFY3-shRNA, respectively. (E) External whole-body fluorescence images of the lung by injection of vector, HOXD9 src-shRNA and HOXD9-RUFY3-shRNA were obtained 42 days after tail vein injection (N = 3). (F) White-light images of orthotopic tumors resulting from hepatic metastases of mice obtaining 42 days. Yellow arrow indicates primary tumor. Yellow arrowheads indicate hepatic metastatic lesions. (G) The numbers of metastatic lesions in the liver were counted. ***, P < 0.001, vector vs. HOXD9. ***, P < 0.001, HOXD9 src-shRNA vs. HOXD9-RUFY3-shRNA, respectively. (H) Metastatic cancer tissues in the liver were stained with H&E. (I)-(N) MMP2 or/and MMP9 expression in tumors derived from AGS cells was determined by qRT-PCR and IHC. ***, P < 0.001, vector vs. HOXD9 and HOXD9 src-shRNA vs. HOXD9-RUFY3-shRNA, respectively. Scale bars, 100 μm in L, M & N. (TIF 9599 kb)

Abbreviations
ChIP: chromatin immunoprecipitation; ERK1/2: extracellular signal-regulated protein kinase; GC: gastric cancer; HOX: Homeobox; JNK: c-Jun N-terminal kinase; p38: p38 mitogen-activated protein kinase; qPCR: real-time quantitative reverse transcription polymerase chain reaction; RLU: relative luciferase unit; RUFY3: RUN and FYVE domain containing 3; Src shRNA: scramble shRNA; TMA: Tissue microarray

Acknowledgments
We acknowledge the generous support of the Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University.

Authors’ contributions
YW, JC and SL designed this study. HZ, WD, JL, LX and XW carried out experiments in vitro. WT, YC, QY, ML performed experiments in vivo. YX, WZ helped with data analysis. JL, JW and GL were responsible for the collection of specimens. YS, PJ and GL contributed to technical support. AL and SL supervised the project and JW wrote the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by grants from the National Natural Science Funds of China (Nos.816122875, 81772964 and 81974448), Guangdong gastrointestinal disease research center (No.2017B010110003) and the Special Scientific Research Fund of Public Welfare Profession of National Health and Family Planning Commission (Grant No.201502026). Special Foundation for Economic and Technological Development of Longgang District, Shenzhen (No: LGKCYLWS2018000160) and NO: LGKCYLWS2018000141).

Availability of data and materials
All remaining data are available within the article and supplementary files, or available from the authors upon request.

Ethics approval and consent to participate
This study was reviewed and approved by the Medical Ethics Committee of Nanfang Hospital (NFECC-2017-062), Southern Medical University, Guangzhou, China. All animal studies were approved by the Institutional Animal Care and Use Committee of Committee of Nanfang Hospital.

Consent for publication
All authors have agreed to publish this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2Department of Gastroenterology, Longgang District People’s Hospital, Shenzhen 518172, China. 3Department of Gastroenterology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510515, China. 4Department of Medical Oncology, The First People’s Hospital of Yunnan Province, Medical School of Kunming University of Science and Technology, Kunming 650032, China. 5Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 6Department of Digestive Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Received: 1 March 2019 Accepted: 28 August 2019
Published online: 23 September 2019

References
1. Moens CB, Selleri L. Hox cofactors in vertebrate development. Dev Biol. 2006;292(1):193–206.
2. Mansour MA, Senga T. HOXD8 exerts a tumor-suppressing role in colorectal cancer as an apoptotic inducer. Int J Biochem Cell Biol. 2017;88:1–13.
3. Hombria JC, Lovegrove B. Beyond homeosis–HOX function in morphogenesis and organogenesis. Differentiation. 2003;71(8):461–76.
4. Liu H, Zhang M, Xu S, Zhang J, Zhou J, Yang C, et al. HOXC8 promotes proliferation and migration through transcriptional up-regulation of TGFβeta1 in non-small cell lung cancer. Oncogenesis. 2018;7:21/1.
5. Rieger E, Bilj JJ, van Oostveen JW, Soyer HP, Dudejans CB, Jiwa NM, et al. Expression of the homeobox gene HOX4A in keratinocytes of normal skin and epithelial skin tumors is correlated with differentiation. J Invest Dermatol. 1994;103(3):341–6.
6. Castronovo V, Kusaka M, Chariot A, Gielen J, Sobel M. Homeobox genes: potential candidates for the transcriptional control of the transformed and invasive phenotype. Biochem Pharmacol. 1994;47(11):137–43.
7. Faella A, Zappavigna V, Navilio F, Boncini E. Inhibition of retinoic acid–induced activation of 3′ human HOXB genes by antisense oligonucleotides affects sequential activation of genes located upstream in the four HOX clusters. Proc Natl Acad Sci U S A. 1994;91(12):5335–9.
8. Liu DB, Gu ZD, Cao XZ, Liu H, Li JY. Immunocytochemical detection of HOXD9 and Pbx1 homeodomain protein expression in Chinese esophageal squamous cell carcinomas. World J Gastroenterol. 2005;11(10):1562–6.
9. Tabuse M, Ohta S, Ohashi Y, Fukaya R, Miwa A, Yoshida K, et al. Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol Cancer. 2011;10(6).
10. Lv X, Li L, Lv L, Qu J, Jin S, Li K, et al. HOXD9 promotes epithelial- mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:133.
11. Wei Z, Sun M, Liu X, Zhang J, Jin Y, Rufy3, a protein specifically expressed in neurons, interacts with actin-bundling protein Fascin to control the growth of axons. J Neurochem. 2014;130(5):678–92.
12. Honda A, Usui H, Sakurama K, Igarashi M. Rufy3 is an adapter protein for small GTPases that activates a Rac guanine nucleotide exchange factor to control neuronal polarity. J Biol Chem. 2017;292(51):20936–46.
13. Yoshida H, Okumura N, Kitagishi Y, Shirafuji N, Matsuda S, Rab5 Q79L interacts with the carboxyl terminus of RUFY3. Int J Biol Sci. 2010;6(2):187–9.
14. Xie R, Wang J, Tang W, Li Y, Peng Y, Zhang H, et al. Rufy3 promotes metastasis through epithelial-mesenchymal transition in cancer cell lines. Cell Death Dis. 2015:6:e1682.
15. Wang G, Zhang Q, Song Y, Wang X, Guo Q, Zhang J, et al. PARK1 regulates RUFY3-mediated gastric cancer cell migration and invasion. Cell Death Dis. 2015:e1682.
16. Xie R, Wang J, Liu X, Wu L, Zhang H, Tang W, et al. RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer. Sci Rep. 2017;7(1):106.
17. Zhang H, Wu X, Xiao Y, Wu L, Peng Y, Tang W, et al. Coexpression of FOXK1 and vimentin promotes EMT, migration, and invasion in gastric cancer cells. J Mol Med. 2018.
18. Peng Y, Zhang P, Huang X, Yan Q, Wu M, Xie R, et al. Direct regulation of FOXK1 by C-Jun promotes proliferation, invasion and metastasis in gastric cancer cells. Cell Death Dis. 2016;7(11):e2480.
19. Liang L, Li X, Zhang X, Lv Z, He G, Zhao W, et al. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMLNL2. Gastroenterology. 2013;144(3):624–35 e4.

20. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5603):1911–2.

21. Bhol N, Suddasen T, Wu X, Anwar S, Karin M, Gallagher E. The MEKK1 PHD ubiquitates c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. Mol Pharmacol. 1998;54(3):453–8.

22. Jerjes DA, Alabdullah M, Alkaabi M, Abduljabbar R, Muftah A, Nolan C, et al. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast Cancer Res Treat. 2014;147(1):25–37.

23. Luo J, Miller MW. Transforming growth factor beta 1-regulated cell proliferation and expression of neural cell adhesion molecule in B104 neuroblastoma cells: differential effects of ethanol. J Neurochem. 1999;72(6):2286–93.

24. Cong Q, Jia H, Li P, Qi S, Yeh J, Wang Y, et al. p38alpha MAPK regulates proliferation and differentiation of osteoclast progenitors and bone remodeling in an aging-dependent manner. Sci Rep. 2017;7:45964.

25. McEwen DG, Peifer M, Puckered, A Drosophila MAPK phosphatase, ensures cell viability by antagonizing JNK-induced apoptosis. Development. 2005;132(17):3935–46.

26. Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D, et al. Lecithin: choline acyltransferase A regulates human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated mitochondria pathways. Mol Cancer. 2016;15:10336.

27. Long W, Foulks CE, Qin J, Lu J, Ding C, Lonard DM, et al. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012;122(18):1889–90.

28. Fister S, Gunthert AR, Aicher B, Paulini KW, Emmons G, Grundker C. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bad. Cancer Res. 2009;69(16):6473–81.

29. Yang L, Ling Y, Zhang Z, Zhao Q, Tang J, J H, et al. ZL11n is a novel nitric oxide-releasing derivative of farnesylethylsuccinic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways. Biochem Biophys Res Commun. 2011;409(4):752–7.

30. Zhi Q, Chen H, Liu Y, Han Y, Wan D, Xu Z, et al. Podocalyxin-like protein promotes gastric cancer progression through interaction with RUN and FYVE domain containing 1 protein. Cancer Sci. 2019;110(1):118–34.

31. Yang J, Kim D, Wu J, Qiu Y. Interaction between tyrosine kinase Etk and a RUN domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking. J Biol Chem. 2002;277(33):30219–26.